Sigma Planning Corp Has $1.24 Million Holdings in Danaher Co. (NYSE:DHR)

Sigma Planning Corp lowered its position in Danaher Co. (NYSE:DHR) by 39.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,336 shares of the conglomerate’s stock after selling 3,521 shares during the quarter. Sigma Planning Corp’s holdings in Danaher were worth $1,235,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of DHR. International Assets Investment Management LLC lifted its position in shares of Danaher by 4.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,449 shares of the conglomerate’s stock worth $359,000 after acquiring an additional 61 shares during the period. Wedge Capital Management L L P NC increased its holdings in Danaher by 10.5% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,320 shares of the conglomerate’s stock valued at $327,000 after purchasing an additional 125 shares in the last quarter. Summit Global Investments increased its holdings in Danaher by 14.9% during the 3rd quarter. Summit Global Investments now owns 2,202 shares of the conglomerate’s stock valued at $546,000 after purchasing an additional 285 shares in the last quarter. Naples Global Advisors LLC acquired a new stake in Danaher during the 3rd quarter valued at $249,000. Finally, Essex LLC acquired a new stake in Danaher during the 3rd quarter valued at $206,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $236.08 on Tuesday. The firm has a market cap of $174.83 billion, a price-to-earnings ratio of 36.95, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. The stock’s 50-day moving average is $248.72 and its 200-day moving average is $230.39. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.87 earnings per share. Equities analysts predict that Danaher Co. will post 7.62 earnings per share for the current fiscal year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 16.90%.

Wall Street Analyst Weigh In

DHR has been the subject of several research reports. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Raymond James lifted their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Royal Bank of Canada lifted their target price on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, Citigroup lifted their target price on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $268.27.

Insiders Place Their Bets

In other news, Director Teri List sold 3,289 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last 90 days. 10.90% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.